Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Authors
Keywords
-
Journal
Journal of Thoracic Oncology
Volume 17, Issue 3, Pages 399-410
Publisher
Elsevier BV
Online
2021-11-03
DOI
10.1016/j.jtho.2021.10.013
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MO01.31 Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor
- (2021) D.S. Hong et al. Journal of Thoracic Oncology
- PS01.07 Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis
- (2021) B. Li et al. Journal of Thoracic Oncology
- 99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation
- (2021) G.J. Riely et al. Journal of Thoracic Oncology
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- (2021) Ferdinandos Skoulidis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%
- (2020) J.F. Gainor et al. ANNALS OF ONCOLOGY
- Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes
- (2020) Xiaoxia Chen et al. Annals of Translational Medicine
- NFE2L2 / KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/ PD‐L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy
- (2020) Xian Xu et al. ONCOLOGIST
- Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer
- (2020) G. Lamberti et al. ANNALS OF ONCOLOGY
- Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer
- (2020) Corrin A. Wohlhieter et al. Cell Reports
- LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma
- (2019) Ana Galan-Cobo et al. CANCER RESEARCH
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
- (2019) E J Aguilar et al. ANNALS OF ONCOLOGY
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- MHC-II neoantigens shape tumour immunity and response to immunotherapy
- (2019) Elise Alspach et al. NATURE
- Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment
- (2018) Sarah A. Best et al. Cell Metabolism
- TP53,STK11andEGFRMutations Predict Tumor Immune Profile and the Response to anti-PD-1 in Lung Adenocarcinoma
- (2018) Jerome Biton et al. CLINICAL CANCER RESEARCH
- Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
- (2018) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
- (2017) Rodrigo Romero et al. NATURE MEDICINE
- STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
- (2016) S. Koyama et al. CANCER RESEARCH
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
- (2016) Joshua D Campbell et al. NATURE GENETICS
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
- (2016) Douglas B. Johnson et al. Nature Communications
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
- (2015) F. Skoulidis et al. Cancer Discovery
- The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer
- (2013) Emilia Kansanen et al. Redox Biology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now